Literature DB >> 20833821

Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Serpil Erzurum1, Sharon I Rounds, Troy Stevens, Micheala Aldred, Jason Aliotta, Stephen L Archer, Kewal Asosingh, Robert Balaban, Natalie Bauer, Jahar Bhattacharya, Harm Bogaard, Gaurav Choudhary, Gerald W Dorn, Raed Dweik, Karen Fagan, Michael Fallon, Toren Finkel, Mark Geraci, Mark T Gladwin, Paul M Hassoun, Marc Humbert, Naftali Kaminski, Steven M Kawut, Joseph Loscalzo, Donald McDonald, Ivan F McMurtry, John Newman, Mark Nicolls, Marlene Rabinovitch, Judy Shizuru, Masahiko Oka, Peter Polgar, David Rodman, Paul Schumacker, Kurt Stenmark, Rubin Tuder, Norbert Voelkel, Eugene Sullivan, Richard Weinshilboum, Mervin C Yoder, Yingming Zhao, Dorothy Gail, Timothy M Moore.   

Abstract

The Division of Lung Diseases of the National Heart, Lung, and Blood Institute, with the Office of Rare Diseases Research, held a workshop to identify priority areas and strategic goals to enhance and accelerate research that will result in improved understanding of the lung vasculature, translational research needs, and ultimately the care of patients with pulmonary vascular diseases. Multidisciplinary experts with diverse experience in laboratory, translational, and clinical studies identified seven priority areas and discussed limitations in our current knowledge, technologies, and approaches. The focus for future research efforts include the following: (1) better characterizing vascular genotype-phenotype relationships and incorporating systems biology approaches when appropriate; (2) advancing our understanding of pulmonary vascular metabolic regulatory signaling in health and disease; (3) expanding our knowledge of the biologic relationships between the lung circulation and circulating elements, systemic vascular function, and right heart function and disease; (4) improving translational research for identifying disease-modifying therapies for the pulmonary hypertensive diseases; (5) establishing an appropriate and effective platform for advancing translational findings into clinical studies testing; and (6) developing the specific technologies and tools that will be enabling for these goals, such as question-guided imaging techniques and lung vascular investigator training programs. Recommendations from this workshop will be used within the Lung Vascular Biology and Disease Extramural Research Program for planning and strategic implementation purposes.

Entities:  

Mesh:

Year:  2010        PMID: 20833821      PMCID: PMC3029941          DOI: 10.1164/rccm.201006-0869WS

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  72 in total

1.  Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension.

Authors:  Todd M Bull; Christopher D Coldren; Mark Moore; Sylk M Sotto-Santiago; David V Pham; S Patrick Nana-Sinkam; Norbert F Voelkel; Mark W Geraci
Journal:  Am J Respir Crit Care Med       Date:  2004-06-23       Impact factor: 21.405

Review 2.  On lung endothelial cell heterogeneity.

Authors:  Sarah Gebb; Troy Stevens
Journal:  Microvasc Res       Date:  2004-07       Impact factor: 3.514

Review 3.  Treatment of pulmonary arterial hypertension.

Authors:  Marc Humbert; Olivier Sitbon; Gérald Simonneau
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

4.  Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.

Authors:  Y Kasahara; R M Tuder; L Taraseviciene-Stewart; T D Le Cras; S Abman; P K Hirth; J Waltenberger; N F Voelkel
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

5.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

6.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.

Authors:  R C Trembath; J R Thomson; R D Machado; N V Morgan; C Atkinson; I Winship; G Simonneau; N Galie; J E Loyd; M Humbert; W C Nichols; N W Morrell; J Berg; A Manes; J McGaughran; M Pauciulo; L Wheeler
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

7.  Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms.

Authors:  Stefan Hein; Eyal Arnon; Sawa Kostin; Markus Schönburg; Albrecht Elsässer; Victoria Polyakova; Erwin P Bauer; Wolf-Peter Klövekorn; Jutta Schaper
Journal:  Circulation       Date:  2003-02-25       Impact factor: 29.690

8.  Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis.

Authors:  M W Geraci; M Moore; T Gesell; M E Yeager; L Alger; H Golpon; B Gao; J E Loyd; R M Tuder; N F Voelkel
Journal:  Circ Res       Date:  2001-03-30       Impact factor: 17.367

9.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.

Authors:  R E Harrison; J A Flanagan; M Sankelo; S A Abdalla; J Rowell; R D Machado; C G Elliott; I M Robbins; H Olschewski; V McLaughlin; E Gruenig; F Kermeen; M Halme; A Räisänen-Sokolowski; T Laitinen; N W Morrell; R C Trembath
Journal:  J Med Genet       Date:  2003-12       Impact factor: 6.318

10.  Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension.

Authors:  A Chaouat; F Coulet; C Favre; G Simonneau; E Weitzenblum; F Soubrier; M Humbert
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

View more
  43 in total

1.  Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Authors:  Harm J Bogaard; Shiro Mizuno; Christophe Guignabert; Aysar A Al Hussaini; Daniela Farkas; Gerrina Ruiter; Donatas Kraskauskas; Elie Fadel; Jeremy C Allegood; Marc Humbert; Anton Vonk Noordegraaf; Sarah Spiegel; Laszlo Farkas; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

2.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Rubin M Tuder; Laura A Davis; Brian B Graham
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

Review 3.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

4.  Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.

Authors:  Daniela Farkas; Aysar A Alhussaini; Donatas Kraskauskas; Vita Kraskauskiene; Carlyne D Cool; Mark R Nicolls; Ramesh Natarajan; Laszlo Farkas
Journal:  Am J Respir Cell Mol Biol       Date:  2014-09       Impact factor: 6.914

5.  Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.

Authors:  Paul B Dieffenbach; Christina Mallarino Haeger; Anna Maria F Coronata; Kyoung Moo Choi; Xaralabos Varelas; Daniel J Tschumperlin; Laura E Fredenburgh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-06-22       Impact factor: 5.464

6.  Pulmonary Hypertension and Precision Medicine through the "Omics" Looking Glass.

Authors:  Jarrod W Barnes; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

7.  Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Authors:  John H Newman; Stuart Rich; Steven H Abman; John H Alexander; John Barnard; Gerald J Beck; Raymond L Benza; Todd M Bull; Stephen Y Chan; Hyung J Chun; Declan Doogan; Jocelyn Dupuis; Serpil C Erzurum; Robert P Frantz; Mark Geraci; Hunter Gillies; Mark Gladwin; Michael P Gray; Anna R Hemnes; Roy S Herbst; Adrian F Hernandez; Nicholas S Hill; Evelyn M Horn; Kendall Hunter; Zhi-Cheng Jing; Roger Johns; Sanjay Kaul; Steven M Kawut; Tim Lahm; Jane A Leopold; Greg D Lewis; Stephen C Mathai; Vallerie V McLaughlin; Evangelos D Michelakis; Steven D Nathan; William Nichols; Grier Page; Marlene Rabinovitch; Jonathan Rich; Franz Rischard; Sharon Rounds; Sanjiv J Shah; Victor F Tapson; Naomi Lowy; Norman Stockbridge; Gail Weinmann; Lei Xiao
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

8.  Hypoxia-induced glucose-6-phosphate dehydrogenase overexpression and -activation in pulmonary artery smooth muscle cells: implication in pulmonary hypertension.

Authors:  Sukrutha Chettimada; Rakhee Gupte; Dhwajbahadur Rawat; Sarah A Gebb; Ivan F McMurtry; Sachin A Gupte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-05       Impact factor: 5.464

9.  SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension.

Authors:  Yufeng Yao; Hui Li; Xinwen Da; Zuhan He; Bo Tang; Yong Li; Changqing Hu; Chengqi Xu; Qiuyun Chen; Qing K Wang
Journal:  Pulm Pharmacol Ther       Date:  2019-01-28       Impact factor: 3.410

10.  Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Authors:  Shiro Mizuno; Laszlo Farkas; Aysar Al Husseini; Daniela Farkas; Jose Gomez-Arroyo; Donatas Kraskauskas; Mark R Nicolls; Carlyne D Cool; Herman J Bogaard; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.